Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 15/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.38 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | TAF1 | P21675 | 1/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683453 | 0.84 | BRD4 (0.48) | BRD9BRD4 | |
| SCHEMBL30811982 | 0.82 | BRD9 (0.46) | BRD9BRD4GABBR2BRD2EP300 | |
| SCHEMBL30812189 | 0.81 | BRD4 (0.44) | BRD9BRD4 | |
| SCHEMBL30824882 | 0.81 | BRD9 (0.50) | BRD9BRD4GABBR2BRD2EP300 | |
| SCHEMBL27393452 | 0.81 | BRD9 (0.50) | BRD9BRD4GABBR2BRD2EP300 | |
| SCHEMBL30812046 | 0.81 | BRD4 (0.36) | BRD4 | |
| SCHEMBL30812047 | 0.80 | BRD4 (0.48) | BRD9BRD4 | |
| SCHEMBL30811961 | 0.79 | EP300 (0.31) | EP300 | |
| SCHEMBL30812178 | 0.78 | BRD4 (0.45) | BRD9BRD4 | |
| SCHEMBL30812004 | 0.77 | BRD4 (0.45) | BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | BRD9 10/4885BRD4 1/4885GABBR2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.